Usefulness of high-sensitivity cardiac troponin t and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy

American Journal of Cardiology

Volumn 112, Issue 6, 2013, Pages 867-872

  Kawasaki, Tatsuya ^a   Sakai, Chieko ^a   Harimoto, Kuniyasu ^a   Yamano, Michiyo ^a   Miki, Shigeyuki ^a   Kamitani, Tadaaki ^a  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIAC MYOSIN LIGHT CHAIN I; CREATINE KINASE MB; GADOLINIUM PENTETATE MEGLUMINE; HIGH SENSITIVITY CARDIAC TROPONIN T; MYOGLOBIN; MYOSIN LIGHT CHAIN; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; IMAGE ENHANCEMENT; LATE GADOLINIUM ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; BLOOD; COMPARATIVE STUDY; FIBROSIS; HEART MUSCLE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RETROSPECTIVE STUDIES; TROPONIN T;

EID: 84886644443     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.04.060     Document Type: Article

References (29)

1. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012;14:13.
2. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855-861.
3. Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology 2011;261: 358-374.
4. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-2264.
5. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010;3: 51-58.
6. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-874.
7. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-887.
8. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012;5:370-377.
9. Cambronero F, Marín F, Roldán V, Hernández-Romero D, Valdés M, Lip GY. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 2009;30:139-151.
10. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;58:e212ee260.
11. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J, Seidman CE. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-563.
12. Kawasaki T, Yamano M, Sakai C, Harimoto K, Miki S, Kamitani T, Sugihara H. Diagnostic performance of ultrasonic tissue characterization for subendocardial ischaemia in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging Epub Dec 7, 2012.
13. Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, Schulz-Menger J. Noninvasive detection of fibrosis applying contrastenhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009;5:284-291.
14. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-542.
15. Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R, Dohi Y. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003;89:1303-1307.
16. Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, Montanari A, Regolisti G, Fiaccadori E, Cabassi A. Serum adipokine zinc a2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metabolism 2012;61:37-42.
17. Toh N, Nishii N, Nakamura K, Tada T, Oe H, Nagase S, Kohno K, Morita H, Kusano KF, Ito H. Cardiac dysfunction and prolonged hemodynamic deterioration after implantable cardioverter-defibrillator shock in patients with systolic heart failure. Circ Arrhythm Electrophysiol 2012;5:898-905.
18. Gomes AV, Barnes JA, Harada K, Potter JD. Role of troponin T in disease. Mol Cell Biochem 2004;263:115-129.
19. Moreno V, Hernández-Romero D, Vilchez JA, García-Honrubia A, Cambronero F, Casas T, González J, Martínez P, Climent V, de la Morena G, Valdés M, Marín F. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail 2010;16:950-956.
20. Sato Y, Taniguchi R, Nagai K, Makiyama T, Okada H, Yamada T, Matsumori A, Takatsu Y. Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart 2003;89:659-660.
21. Payá E, Marín F, González J, Gimeno JR, Feliu E, Romero A, Ruiz- Espejo F, Roldán V, Climent V, de la Morena G, Valdés M. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail 2008;14:414-419.
22. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011;278:1808-1817.
23. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-461.
24. Magga J, Sipola P, Vuolteenaho O, Risteli J, Jääskeläinen P, Peuhkurinen K, Kuusisto J. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. Am J Cardiol 2008;101:1185-1190.
25. de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J 2012;163:821-828.
26. Meune C, Drexler B, Haaf P, Reichlin T, Reiter M, Meissner J, Twerenbold R, Stelzig C, Freese M, Winkler K, Mueller C. The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart 2011;97:1479-1483.
27. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol 2012;60:960-968.
28. Keller T, Münzel T, Blankenberg S. Making it more sensitive: the new era of troponin use. Circulation 2011;123:1361-1363.
29. Popp RL. Troponin: messenger or actor? J Am Coll Cardiol 2013;61: 611-614.